Gastrointestinal (GI) diseases can be complex, debilitating, and life-changing. For more than 25 years, Takeda and our collaboration partners have focused on improving the lives of patients through the delivery of innovative medicines and dedicated patient disease support programs. Takeda is leading in areas of gastroenterology associated with high unmet need, such as inflammatory bowel disease, acid-related diseases and motility disorders. Our R&D organization is investigating new treatments for inflammatory bowel disease, celiac and other luminal gut diseases, motility disorders and liver diseases.
Inflammatory Bowel Disease
Ulcerative colitis (UC) and Crohn’s disease (CD) are marked by inflammation in the lining of the gastrointestinal tract. UC impacts the large intestine only, which includes the colon and the rectum, while CD can impact any part of the digestive tract, and predominantly affects the ileum. There is no known cause for UC and CD, although many researchers believe that the interaction between genes, the body’s immune system, and environmental factors may play a role.
Chronic Idiopathic Constipation
Chronic Idiopathic Constipation (CIC) is characterized by difficult, infrequent or incomplete passage of stools over a prolonged period and a range of symptoms, which may include abdominal pain and/or bloating. The condition, which affect about 14% of the adult population, has many potential causes. One of the possible underlying problems is an impairment or dysfunction of the gut’s ability to move, by contracting and releasing, naturally. CIC can significantly impact a person’s life and increase in medical care.
Short Bowel Syndrome
Short Bowel Syndrome (SBS) is a serious, chronic, and rare condition that may happen when a large part of the intestine (bowel) is removed (or resected) during surgery. After this surgery, a person will have less large intestine and/or small intestine. The remaining bowel may not be able to absorb enough nutrients from food and drink. This is called malabsorption. Malabsorption puts people at risk for diarrhea, dehydration, electrolyte disturbances, and malnutrition. A goal of SBS treatment is to restore the remaining intestine’s ability to absorb nutrients and reduce long-term dependence on parenteral support (PS).
Gastroesophageal reflux disease
Gastroesophageal reflux disease, or GERD, occurs when stomach acid used for digestion repeatedly backs up, or refluxes, into the esophagus. GERD is also known as acid reflux disease. Heartburn, often described as pain or burning in the chest, is a common symptom of GERD. Other symptoms include sour taste in the mouth, burning in the throat, and burping. With continued exposure to stomach acid, the esophagus may become irritated and possibly even damaged, a condition known as erosive esophagitis.